SOURCE: Wall Street News Alert

Wall Street News Alert

June 10, 2010 09:38 ET

Wall Street News Alert: Breaking News: WKBT -- June 10, 2010

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL--(Marketwire - June 10, 2010) -  Wall Street News Alert's "stocks to watch" this morning are: Weikang Bio-Technology Company, Inc. (OTCBB: WKBT), Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA), Merck & Co Inc (NYSE: MRK) and Perrigo Company (NASDAQ: PRGO).

Yesterday after the markets closed, Weikang Bio-Technology Company, Inc. (OTCBB: WKBT) issued a press release announcing that it is launching a new project to research and develop licorice flavonoids for use in therapeutics.

According to the release, Weikang anticipates sales of therapeutics derived from the project will add approximately $13 million to annual revenue and approximately $5.7 million in annual after-tax net income.

Licorice contains glycyrrhetinic acid, which, in addition to being widely used as a flavoring agent, has also been shown to be effective in treating conditions and afflictions such allergies, hepatitis, inflammation and swelling, including peptic ulcers, hypertension, excessive potassium in the body, skin conditions, viral infections, tumor formation and weight loss.

"We are extremely excited to launch the Licorice Flavonoid Project which we believe will be one of the premier sources in China for research and development of extracting and use of glycyrrhetinic acid as a therapeutic. Glycyrrhetinic acid has been proven to provide numerous health benefits for a variety of ailments and through the use of our state-of-the-art technology we expect to be able to produce high quality therapeutics using this important medicinal compound," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Moreover, Heilongjiang Association of TCM conducted a study at our request on the therapeutic benefits of licorice flavonoids and verified that there are multiple benefits to be derived from this compound and is providing their full support for the project.

In addition to the research, development and production of licorice flavonoid based therapeutics, the Licorice Flavonoid Project will directly benefit the local economy by adding jobs, increasing investment in technology and boosting demand for local licorice planting and processing. Due to the positive effects on the local economy, preferential tax treatments from the government are anticipated.

The total investment for the Licorice Flavonoid Project is expected to be $6.58 million, including $2.93 million in R&D; and the first full year of production expected to yield a return on investment of 86%. The construction of the new factory and purchase of equipment will start upon the successful completion of the R&D. Weikang is targeting to begin production of therapeutics developed from glycyrrhetinic acid in 2011 and to reach the full design output of the new factory by 2012.

The stock closed yesterday at $2.75 a share.

For an in-depth profile of Weikang Bio-Technology Company, visit http://www.wallstreetnewsalert.com/view-company-profiles.php?profile=WKBT_060910.

To receive FREE Mobile Stock Alerts formatted especially for your cell phone, text the word "press" in the subject line to 68494.

For more information, please visit www.WallStreetNewsAlert.com and you can also follow Wall Street News Alerts on Twitter at http://twitter.com/wsna

Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) up 0.05% on 7.8 million shares traded. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company.

Merck & Co Inc (NYSE: MRK) down 0.3% on 12.8 million shares traded. 
Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products.

Perrigo Company (NASDAQ: PRGO) up 1.1% on 1.5 million shares traded.
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products.

Market Commentary:
Wholesale inventories increased 0.4 percent last month after a 0.7 percent gain in March, the Commerce Department said Wednesday.

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at info@wallstreetnewsalert.com

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of often-overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 200 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com.

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street Capital Funding LLC (WSCF), also doing business as Wall Street News Alert maintains a contractual, working relationship with Stock Market Alerts LLC and its' Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release may or may not have approved the statements made in this release and may or may not have approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information, information supplied by third parties or WSCF's own research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. To comply with Section 17(b) of the Securities Act of 1933, WSCF is disclosing that the company has been compensated for dissemination of this information on behalf of one or more of the companies mentioned in this release. Weikang Bio-Technology Company, Inc. (OTCBB: WKBT), WSCF has been compensated Twenty One Thousand and Five Hundred Dollars, by third party, DSC Holdings LLC., who is non-affiliated and may hold a significant position in the stock. WSCF holds no shares of the stock. WSCF may receive compensation for future services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. In the event of any receipt of such shares, full disclosure would be shown above. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information